Detection of aluminum in lumbar spinal cord of sheep subcutaneously inoculated with aluminum-hydroxide containing products by Miguel, RD et al.
Journal Pre-proof
Detection of aluminum in lumbar spinal cord of sheep
subcutaneously inoculated with aluminum-hydroxide containing
products
Ricardo de Miguel, Javier Asín, Ana Rodríguez Largo, Jéssica
Molín, Irache Echeverría, Damián de Andrés, Marta Pérez,




To appear in: Journal of Inorganic Biochemistry
Received date: 30 July 2019
Revised date: 13 September 2019
Accepted date: 27 September 2019
Please cite this article as: R. de Miguel, J. Asín, A.R. Largo, et al., Detection of aluminum
in lumbar spinal cord of sheep subcutaneously inoculated with aluminum-hydroxide
containing products, Journal of Inorganic Biochemistry (2019), https://doi.org/10.1016/
j.jinorgbio.2019.110871
This is a PDF file of an article that has undergone enhancements after acceptance, such
as the addition of a cover page and metadata, and formatting for readability, but it is
not yet the definitive version of record. This version will undergo additional copyediting,
typesetting and review before it is published in its final form, but we are providing this
version to give early visibility of the article. Please note that, during the production
process, errors may be discovered which could affect the content, and all legal disclaimers
that apply to the journal pertain.









P a g e  1 | 24 
 
Detection of Aluminum in Lumbar Spinal Cord of Sheep 
Subcutaneously Inoculated with Aluminum-Hydroxide Containing 
Products 
#Ricardo de Miguel1, #Javier Asín1, Ana Rodríguez Largo1, Jéssica Molín1, 
Irache Echeverría2, Damián de Andrés2, Marta Pérez3,5, Ignacio de Blas1,5, 
Matthew Mold4, Ramsés Reina2, *Lluís Luján1,5 
1 Department of Animal Pathology, University of Zaragoza, Spain 
2 Institute of Agrobiotechnology, CSIC- Government of Navarra, Mutilva Baja, 
Navarra, Spain 
3 Department of Animal Anatomy, Embryology and Genetics, University of 
Zaragoza, Spain 
4 The Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire 
ST5 5BG, UK 
5 Instituto Universitario de Investigación Mixto Agroalimentario de Aragón (IA2), 
University of Zaragoza, Spain 
# Both authors contributed equally 
*Corresponding Author: 
Lluís Luján 
E-mail: Lluis.Lujan@unizar.es  
Phone Number: (+34) 976 76 28 17 
Postal Address: Miguel Servet street, 177.  
Department of Animal Pathology. 
University of Zaragoza. 











P a g e  2 | 24 
Abstract:  
The use of vaccines containing aluminum (Al) adjuvants is widespread in 
ovine production. Al adjuvants induce an effective immune-response but lead 
to the formation of post-vaccination granulomas from which Al can 
disseminate. This work aims to study the accumulation of Al in the central 
nervous system of sheep subcutaneously inoculated with Al-hydroxide 
containing products. Lumbar spinal cord and parietal lobe from 21 animals 
inoculated with 19 doses of Vaccine (n=7), Adjuvant-only (n=7) or phosphate-
buffered saline as Control (n=7) were analyzed with transversely heated 
graphite furnace atomic absorption spectroscopy and lumogallion staining for 
Al analytical measurements and Al tisular localization respectively. In the 
lumbar spinal cord, Al median content was higher in both the Adjuvant-only 
and Vaccine group (p=0.001) compared with the Control group. Animals of 
the Adjuvant-only group showed the higher individual measurements in the 
lumbar spinal cord (14.36 μg/g and 7.83 μg/g). In the parietal lobe, Al median 
content tended to be higher in the Adjuvant-only group compared with 
Control group (p=0.074). Except for three replicates of the Adjuvant-only 
group, Al content was always below 1 μg/g. In the lumbar spinal cord, 
lumogallion reactive Al deposits were more abundant in the gray matter than 
in the white matter in both Vaccine (p=0.034) and Adjuvant-only groups 
(p=0.017) and Al deposits were mostly associated with glial-like cells 
(p= 0.042). In the parietal lobe, few Al deposits, which were sometimes 
related to vessels, were found. In sheep, Al-hydroxide adjuvants inoculated in 
the subcutaneous tissue selectively accumulates in the lumbar spinal cord. 
Keywords: Aluminum hydroxide; Aluminum-based vaccines; sheep; ovine; 
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1. Introduction 
Vaccines are key elements for controlling diseases in animal populations. 
From the 1930s, vaccines have made a major contribution to improving sheep 
health, welfare and productivity [1]. The ovine health programs in South-
Europe usually involve vaccination against common reproductive, digestive 
and respiratory pathogens [2]. The vaccination schedule of each flock largely 
depends on management system, production type, breed and local climate [2]. 
In our local conditions (meat-producing breeds managed in semi-intensive to 
intensive systems that often implies shepherding), animals usually receive 
between 2-4 vaccines per year during their whole lifespan. 
The majority of modern vaccines need an adjuvant to strengthen the 
humoral and cellular immune responses induced against the vaccine antigen 
[3]. Most ovine vaccines use aluminum (Al) hydroxide as adjuvant which 
induces a fast and effective immune-response against vaccine antigens. This 
adjuvant consists of primary nano-sized particles that spontaneously 
aggregate forming micron-sized agglomerates subjected to marked size 
variations depending on Al-hydroxide concentration, ionic strength of the 
diluent and antigen absorption [4,5]. The mechanism of action of Al-hydroxide 
adjuvants remains unclear although recent data indicate that stimulation of the 
inflammasome may play a major role [6,7].  
A variety of post-vaccination secondary effects have been described in 
animal species [8–12]. Specifically, in sheep, Al-based vaccines have been 
associated with the ovine autoimmune/inflammatory syndrome induced by 
adjuvants (ovine ASIA syndrome) [13]. This complex syndrome was described 
after the compulsory European vaccination campaigns against bluetongue 
virus of ruminants and can still be detected nowadays associated with other 










P a g e  4 | 24 
In sheep, Al-hydroxide is phagocytosed by macrophages inducing the 
formation of persistent sterile subcutaneous granulomas, from which 
intracytoplasmic Al-hydroxide can translocate by leukocyte trafficking to the 
regional lymph node [15]. In mice, lymph node plays a key role in Al 
biodistribution enabling intramacrophagic Al to reach distant tissues such as 
the spleen and central nervous system (CNS) [16,17]. Whether Al-hydroxide 
can reach other locations in the sheep body after subcutaneous injection of Al-
hydroxide alone or formulated in Al-based vaccines is unknown. The aim of 
this work is to determine the presence of Al in the CNS of sheep after 
subcutaneous injection of Al-hydroxide containing products and to study the 
localization of this Al within the neuroparenchyma. 
2. Materials and Methods 
2.1. Animals 
All experimental procedures were approved and licensed by the Ethical 
Committee of the University of Zaragoza (PI15/14). Animal samples analyzed 
in this work belonged to a previous, wider study carried out by our group that 
aimed to study the local and systemic effects caused by repetitive 
subcutaneous inoculation of Al-containing adjuvants in sheep [15]. Briefly, 
twenty-one, three-month-old, neutered male purebred Rasa Aragonesa lambs 
were selected from a pedigree flock of certified good health and lodged indoor 
at the experimental farm of the University of Zaragoza, with optimal conditions 
of housing, management and diet for 15 months. 
Based on the received treatment, animals were divided into 3 groups of 7 
animals each and were inoculated with different substances: Vaccine group 
was treated with commercial vaccines, Adjuvant-only group was inoculated 
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received phosphate-buffered saline (PBS). Animals had never been 
vaccinated or inoculated with any other substance prior to the experiment. 
Lambs underwent an accelerated vaccination scheduled to mimic, in an 
acceptable time frame for an experimental project, the Al load that these 
animals can receive in field conditions during their lifespan. Inoculations were 
performed in the subcutaneous tissue of the flank. A total of 19 inoculations 
were distributed in 15 injection dates. The schedule of injections for the three 
groups and the vaccines used are detailed in Figure S1 and Table S1 
respectively. Al content of each inocula was mesured by inductively coupled 
plasma mass spectrometry. Vaccine and Adjuvant-only groups received a total 
of 81,29 mg of Al per animal. Al content of PBS inocula was always under the 
limit of detection of the technique (0.074 µg/mL). At the end of the study 
animals were eutanished and systematic tissue sampling was performed. 
2.1. Aluminum content in lumbar spinal cord and parietal lobe 
Al content in the lumbar spinal cord and the parietal cerebral lobe was 
determined in all animals by transversely heated graphite atomic absorption 
spectroscopy (TH-GFAAS) using an established method [18]. Briefly, three 
replicate portions of 0.3-0.5 g from the parietal lobe and lumbar spinal cord of 
each animal were dried in a 37°C incubator until reaching a constant weight. A 
mixture of 1 mL 15.8 M HNO3 and 1 mL of 30 % w/v H2O2  was used to digest 
each replicate in a microwave (MARS Xpress CEM Microwave Technology 
Ltd.). After digestion, samples were diluted with ultrapure water to reach a final 
volume of 5 mL. Total Al content was measured by an atomic absorption 
spectrometer with a transversely heated graphite atomizer and longitudinal 
Zeeman-effect background corrector and an AS-80 autosampler with 
WinLab32 software (Perkin Elmer, UK). Determinations were calculated by 
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signal and each determination was the arithmetic mean of three sample 
injections with a relative standard deviation of 10 %. Results were expressed 
as μg Al/g tissue dry weight.  
2.2. Aluminum localization in lumbar spinal cord and parietal lobe 
Lumogallion staining was performed in formalin-fixed paraffin-embedded 
tissues of the lumbar spinal cord and parietal lobe following a recently 
validated method which is highly specific for Al detection in tissues [19]. 
Briefly, 5 μm-thick tissue sections carefully protected from environmental Al 
contamination were dewaxed, rehydrated and incubated for 45 minutes with a 
1 mM solution of lumogallion (Tokyo Chemical Industry, UK) buffered in 50 
mM 1,4-Piperazine-diethanesulfonic acid buffer (PIPES-buffer) pH 7.4. Serial 
sections from each tissue were used as controls for evaluation of tissue 
autofluorescence. The control sections followed the same protocol but they 
were incubated only with PIPES-buffer solution. After incubation, all slides 
were washed 6 times with PIPES-buffer solution, rinsed in ultrapure water, 
mounted with an aqueous medium and stored at 4ºC overnight prior to 
analysis. Lumogallion and control autofluorescence analyses were performed 
using a fluorescence microscope (Zeiss AxioVert 200M, Germany) with a 
bandpass excitation filter (470/40 nm), beam splitter (495nm) and bandpass 
emission filter (590/33 nm). Excitation of the Al-lumogallion complex emits 
characteristic yellow-orange fluorescence. Autofluorescence of immediately 
adjacent serial sections confirmed lumogallion fluorescence as indicative of Al 
staining. Images were taken with AxioCam HR and processed with analyses 
software package AxioVision 4.6.3. Total evaluated area was approximately 
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2.2. Statistical analysis 
Shapiro-Wilk´s test was used to check if the data of the quantitative 
variables (i.e. Al content and Al deposits) met the assumptions of normality. 
As none of them met the assumptions, they were considered non-normal, thus 
they were described using median and interquartile range (IQR). Data were 
graphically represented using box and whiskers plots, where boxes represent 
the IQR (IQR=Q3-Q1) and contain 50 % of the data. Whisker bars were 
calculated from the IQR (Upper: Q3 + 1.5 x IQR; lower: Q1 – 1.5 x IQR), and 
reflect the variability of the data outside Q1 and Q3. 
In non-normal non-paired variables (i.e. comparisons of the content in Al 
in the CNS among the three groups) association of a non-normal quantitative 
variable with a qualitative variable with three or more categories was assessed 
by Kruskal-Wallis test followed by post hoc Dunn’s test [20]. In non-normal 
paired variables (i.e. comparisons of Al deposits in the gray matter and white 
matter) the association between variables was assessed by Wilcoxon test 
[20]. 
3. Results 
3.1. Aluminum c ntent in lumbar spinal cord and parietal lobe 
The content of Al within all tissue replicates measured in the lumbar spinal 
cord is detailed in Table 1. Only in the Control group were more than half of 
the replicates (11/21, 52 %) below 0.01 μg/g. Two animals (111 and 113) 
within the Adjuvant-only group presented two high (over 2 μg/g) replicates 
each. Adjuvant-only and Vaccine groups (Adjuvant-only: median=0.49 μg/g, 
IQR=0.31-1.04; Vaccine: median=0.39 μg/g, IQR=0.33-0.62) showed a 
significantly (p=0.001) higher Al content than the Control group (median=0.08 
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The content of Al within all tissue replicates measured in the parietal lobe is 
detailed in Table 2. Replicates in the three groups were homogeneous, with 
most of the values below 1 μg/g. Within the Adjuvant-only group there were 
three replicates over this value. Al content in the Adjuvant-only group 
(median=0.2 μg/g, IQR=0.11-0.73) tended to be higher (p=0.074) when 
compared with the Control group (median=0.1 μg/g, IQR=0.01-0.26) whereas 
none of these two groups differed with the Vaccine group (median=0.1 μg/g, 
IQR=0.01-0.35). A comparison between groups is shown in Figure 2. 
3.2. Aluminum localization in lumbar spinal cord and parietal lobe 
Details of Al deposits found in the CNS (lumbar spinal cord and parietal 
lobe) are shown in Tables S2 and S3. Lumogallion reactive deposits, showing 
a yellow-orange fluorescence emission were observed in both, lumbar spinal 
cord and parietal lobe and they were identified as Al after autofluorescence 
verification. The vast majority of Al deposits were located in the gray matter, 
they were micron-sized (1-10µm approx.) and were mostly cell-associated. 
Deposits were significantly more abundant in the lumbar spinal cord than in 
the parietal lobe in the Adjuvant-only group (p=0.027) and they showed a 
marked trend in the Vaccine group (p=0.054). All animals of the Adjuvant-only 
group and Vaccine group showed at least one Al deposit in the lumbar spinal 
cord. The total number of deposits at lumbar spinal cord were similar in 
Vaccine (22) and Adjuvant-only (21) groups and they significantly differed 
(p=0.002 and p=0.001 respectively) from the Control group (2). In the lumbar 
spinal cord, Al deposits were significantly more abundant in the gray matter 
(Figure 3) than in the white matter in both Vaccine (p= 0.034) and Adjuvant-
only (p= 0.017) groups. Al deposits in the gray matter of the lumbar spinal cord 










P a g e  9 | 24 
(Figure 4a, 4b) and only a few deposits were non-cell associated (Figure 4c, 
4d), this difference being statistically significant (p= 0.042).  
In the parietal lobe, Al was mostly found in the gray matter of the Vaccine 
group, in sharp contrast to Adjuvant-only (p=0.017) and Control groups 
(p=0.017). These deposits were cell-associated and sometimes closely related 
to vessels (Figure 5). The Al deposits observed in the parietal lobe was 
strickingly lower in contrast with the deposits found in the lumbar spinal cord 
(Tables S2 and S3). 
4. Discussion 
In sheep, Al-containing products lead to the formation of subcutaneous 
granulomas from where intramacrophagic Al-hydroxide can reach the regional 
lymph node and potentially disseminate to other organs [15]. This is the first 
work that studies accumulation of Al in the CNS of sheep after subcutaneous, 
repeated injections of Al-containing products. Al was quantitatively measured 
by TH-GFAAS and localized by lumogallion staining in lumbar spinal cord and 
parietal lobe. 
The Adjuvant-only and Vaccine groups presented higher Al levels in the 
spinal cord compared with the Control group. The difference was more 
marked in the Adjuvant-only group and, indeed, the highest individual 
replicates were obtained in animals from this group. One animal in the 
Adjuvant-only group presented two replicates of 2.14 μg/g and 14.36 μg/g 
each, while another presented two replicates of 7.83 μg/g each. The variability 
between replicates within the same animal is attributed to the characteristic 
patchy distribution of Al within tissues, which does not diffuse homogeneously 
[18,19,21]. In measurements performed in human brain tissue with this 
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pathologic [19]. The Vaccine group did not show high replicates in the lumbar 
spinal cord. The highest measurement in this group was 1.23 μg/g. 
Nevertheless, the median Al levels were significantly higher than in the Control 
group, which showed similar low levels to the brain tissue. Interestingly, more 
than half (11/21, 52%) of all replicates measured in the lumbar spinal cord of 
the Control group were below 0.1 μg/g. 
The presence of higher lumbar spinal cord levels of Al in the Adjuvant-
only group than in the Vaccine group could be related to the demonstrated 
decreased persistence of post-vaccination granulomas at the subcutaneous 
level in the Adjuvant-only group and also to the smaller size of Al particles 
contained in intramacrophagic aggregates [15]. It is known that size of Al-
hydroxide aggregates depends on Al-hydroxide concentration, ionic strength 
of the milieu and antigen affinity [5]. Shardlow et al. have shown that prior to 
the inoculation into the animal, Al-hydroxide aggregates present in the inocula 
are notably larger in vaccine formulations (4,2 µm median size) in contrast 
with Adjuvant-only solutions diluted into physiological saline (2,8 µm median 
size) [5]. The optimal size range of particles for macrophagic phagocytosis is 
2-3 um [22]. In vitro studies show that larger size of Al-hydroxide aggregates is 
related with delayed macrophagic internalization and increased cell toxicity 
and death [6,23]. This scenario could explain the earlier mobilization and 
systemic distribution of Al from the granulomas in the Adjuvant-only group as 
well as the increased cell death and necrosis observed in the Vaccine group 
[15]. Actually, murine studies show that the size of Al-adjuvant particles play a 
key role in systemic Al biodistribution and their accumulation in the CNS 
[16,17]. Interestingly, in mice this accumulation is inversely related to the 
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Most of the replicates measured in the parietal lobe were within the same 
limits in the three treatment groups. Just the Adjuvant-only group presented a 
few slightly higher replicates. This is similar to some findings observed in mice 
inoculated intramuscularly, which failed to demonstrate Al accumulation in the 
brain at 270 days after first inoculation, although subcutaneous inoculation in a 
subsequent experiment demonstrated translocation of Al adjuvants into the 
CNS [24]. In our large animal experimental model, maybe the 15-month 
experiment was not long enough to permit significant Al input into the CNS. 
As our data represents the first Al measurements performed in ovine 
nervous tissue (Tables 1 and 2) the values obtained in the Control group will 
be considered as the reference values for normal Al levels in sheep: this being 
so, a range of 0.01 – 0.26 μg/g with a median of 0.1 μg/g in the brain; and a 
range 0.01 – 0.44 μg/g with a median of 0.08 μg/g in the lumbar spinal cord. 
These values contribute to the set of levels established in other models, such 
as mice, rats, and rabbits [25–28], and will be the starting point for further 
studies to be performed in sheep. 
Lumogallion is a highly specific fluorescent stain for Al localization in CNS 
[19] that has been widely validated in a variety of animal species [15,29,30] 
and is useful for detecting Al adjuvants [31,32]. In this study, Al was primarily 
located in the gray matter and was usually associated with glial-like cells in 
sections from both, lumbar spinal cord and parietal lobe. In agreement with the 
analytical measurements of Al obtained by TH-GFAAS, lumogallion reactive Al 
deposits were more abundant in the lumbar spinal cord than in the parietal 
lobe. The former location showed more Al deposits than the latter, what is in 
concordance with the results obtained by TH-GFAAS. Interestingly, in the 
parietal lobe Al was found in close proximity to blood vessels and it was likely 
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location, the presence of this vascular-associated Al particles could support 
the hypothesis of the hematogenous dissemination of Al-loaded macrophages 
from the regional lymph node via the efferent lymphatics and the thoracic duct 
[16]. In the lumbar spinal cord, most Al deposits were found likely associated 
with glial cells, something that has been previously described in translocation 
studies of intramuscularly inoculated Al based adjuvants in mice [16,17]. The 
prevalence of Al-associated glial-like cells reinforce the idea of an Al input to 
the CNS via Al-loaded macrophages [16]. Indeed, previous studies in mice 
have demonstrated Al particles within astroglial and microglial cells [16]. 
Moreover, Al-hydroxide has been shown to increase microglial cell density in 
mice [17]. 
All lumogallion positive deposits found in the present study were dense 
micron-sized aggregates of Al that were predominantly cell-associated and 
located in the gray matter. Such characteristics were similar to those 
described in murine studies of Al adjuvants distribution [16]. However, these 
results contrast with other studies in which Al of unknown origin and 
composition was also found in human CNS as diffuse and plaque-like deposits 
[30,33]. Our results may suggest that both different routes of entry and 
different chemical compositions of Al components, may play a major role in 
the distribution and histopathological morphology of Al in the CNS. 
A limitation of the study could be the number of CNS samples analyzed. 
The three replicates used to quantitatively determine Al levels represented a 
total of 0.9–1.5 g per brain, which accounts for about 1% of the total brain 
weight [34]. Likewise, Al detection in tissue sections by fluorescence 
microscopy also represented a limited sampling of the CNS. Another limitation 
of the study could be the accelerated vaccination schedule. Although the 
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experimental vaccination schedule was designed to be able to detect 
clinicopathologic changes in experimental animals within 15 months. The 
outcome of the same amount of Al divided in small doses for a longer period 
of time might differ from the results of the present study. 
In any case, our results suggest that sheep selectively accumulate 
subcutaneously injected Al in the lumbar spinal cord. This selective 
accumulation of Al may be due to morphological and physiological differences 
between the blood-brain barrier (BBB) and the blood-spinal cord barrier 
(BSCB) [35]. In normal conditions, BSCB present decreased expression of 
tight junction proteins (ZO-1 and occludin) and adherence junction proteins 
(VE-cadherin and β-catenin) and it is more permeable to proinflammatory 
cytokines as IFNγ and TNFα than BBB [35,36]. Moreover, studies in mice 
shows that IFNγ passage through the BBB is saturated at low doses whereas 
BSCB remains non saturated in the lumbosacral region at the same doses 
[36]. This increased permeability in the lumbar spinal cord has been proposed 
to play a role in certain processes such as experimental immune 
encephalomyelitis [37]. This permeability could also account for different input 
of Al into the CNS either by a direct mechanism, favoring the leukocyte 
trafficking or indirectly, accelerating a local neuroinflammatory status which 
has already been related with higher Al input into the CNS [16,37]. 
Alternatively, a weak BSCB at the lumbar area may be contributing to this 
selective accumulation as already demonstrated in mice with a leaky BBB 
[16].  
Selective accumulation of Al in the lumbar spinal cord could be linked to 
the lesions observed in the chronic phase of the ovine ASIA syndrome, where 
neurodegenerative changes were mostly observed at the lumbar spinal cord 
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neuropathological problems as Al is a potential neurotoxic molecule [38]. In 
this sense, animals of the Vaccine and Adjuvant-only groups exhibited 
behavioral changes, characterized by decreased affiliations, increased 
aggressive interactions, and increased stereotypies together with increased 
cortisol levels (J. Asín, manuscript in preparation). Complete histopathological 
study of the CNS is currently being performed to further clarify these aspects.  
5. Conclusions 
Al analytical measurements and fluorescent Al deposits indicate that, in 
sheep, the subcutaneous and intensive injection of Al adjuvants increase the 
levels of Al in the lumbar spinal cord. 
6. Table of Abbreviations 
Al:   Aluminum 
ASIA:   Autoimmune/Inflammatory Syndrome Induced by Adjuvants 
CNS:   Central Nervous system 
PBS:  Phosphate-buffered saline 
TH-GFAAS:  Transversely Heated Graphite Atomic Absorption Spectroscopy 
PIPES-buffer: 1,4-Piperazine-diethanesulfonic acid buffer 
IQR:   Interquartile Range 
BBB:   Blood-brain barrier 
BSCB:  Blood-spinal cord barrier 
6. Acknowledgments: We deeply thank Victor Sorribas for his kind help with 
the fluorescence studies. Charo Puyó and Santiago Becerra are 










P a g e  15 | 24 
7. Funding: RM is a PhD student funded by the Department of Innovation, 
Research and University of Aragon, Spain. JA and ARL are PhD students 
funded by the Spanish Ministry of Science, Innovation and Universities 
(formerly Spanish Ministry of Education). This work was funded by grants from 
the Spanish Ministry of Economy and Industry (AGL2013-49137-C3-1-R and 
RTI2018-096172-B-C33), the Ministry of Science, Innovation and Universities 
(RTI2018-096172-B-C31 and RTI2018-096172-B-C33) and the Government of 
Aragón (A17_17R, Animal Health and Reproduction). 
8. Author Contributions: RM and JA equally contributed to this work and 
wrote the manuscript. RM, ARL, IE and MM performed and interpreted the 
lumogallion studies. JA performed and interpreted the TH-GFAAS studies. 
RM, JA, JM and NB performed the statistical and critical analysis of the data 
obtained. DA, RR, MP and LL were in charge of conceptualization of the work, 
methodology followed, funding acquisition and project administration. 
Conflicts of Interest: Authors declare no conflicts of interest with respect to 










P a g e  16 | 24 
9. References 
[1] Guidelines: Responsible use of vaccines and vaccination in sheep 
production, in RUMA Alliance, 2009, pp. 1-29. 
[2] D. Lacasta, L.M. Ferrer, J.J. Ramos, J.M. González, A. Ortín, G.C. 
Fthenakis, Vet. Micobiol. 181 (2015) 34–46.  
[3] T.B. Ruwona, H. Xu, X. Li, A.N. Taylor, Y.-C. Shi, Z. Cui, Vaccine. 34 
(2016) 3059–3067. 
[4] H. Eidi, M.O. David, G. Crépeaux, L. Henry, V. Joshi, M.H. Berger, M. 
Sennour, J. Cadusseau, R.K. Gherardi, P.A. Curmi, BMC Med. 13 
(2015) 114 
[5] E. Shardlow, M. Mold, C. Exley, Front. Chem. 4 (2016) 48. 
[6] E. Shardlow, M. Mold, C. Exley, Allergy Asthma Clin. Immunol. 14 
(2018) 80. 
[7] S.C. Eisenbarth, O.R. Colegio, W. O’connor, F.S. Sutterwala, R.A. 
Flavell, Nature. 453 (2008) 1122–1126. 
[8] K. Ohmori, K. Masuda, M. Sakaguchi, Y. Kaburagi, K. Ohno, H. 
Tsujimoto, J. Vet. Med. Sci. 64 (2002) 851–853.  
[9] G.E. Moore, N.W. Glickman, M.P. Ward, K.S. Engler, H.B. Lewis, L.T. 
Glickman, J. Am. Vet. Med. Assoc. 226 (2005) 909–912.  
[10] G.E. Moore, L.F. Guptill, M.P. Ward, N.W. Glickman, K.K. Faunt, H.B. 
Lewis, L.T. Glickman, J. Am. Vet. Med. Assoc. 227 (2005) 1102–1108.  
[11] T. Tung, D. Phalen, J. A. Toribio, Aust. Vet. J. 93 (2015) 405–411.  
[12] J.L. Valli, Can. Vet. J. 56 (2015) 1090–1092.  










P a g e  17 | 24 
S. Irusta, J. Santamaría, N. Insausti, Y. Cortés, L. Figueras, I. 
Cuartielles, M. Vila, E. Fantova, J.L.G. Chapullé, Immunol. Res. 56 
(2013) 317–324.  
[14] J. Asín, M. Pérez, P. Pinczowski, M. Gimeno, L. Luján, Immunol. Res. 
66 (2018) 777–782.  
[15] J. Asín, J. Molín, M. Pérez, P. Pinczowski, M. Gimeno, N. Navascués, 
A. Muniesa, I. de Blas, D. Lacasta, A. Fernández, L. de Pablo, M. Mold, 
C. Exley, D. de Andrés, R. Reina, L. Luján, Vet. Pathol. 56 (2019) 418–
428. 
[16] Z. Khan, C. Combadière, F.-J. Authier, V. Itier, F. Lux, C. Exley, M. 
Mahrouf-Yorgov, X. Decrouy, P. Moretto, O. Tillement, R.K. Gherardi, J. 
Cadusseau, BMC Med. 11 (2013).  
[17] G. Crépeaux, H. Eidi, M.O. David, Y. Baba-Amer, E. Tzavara, B. Giros, 
F.J. Authier, C. Exley, C.A. Shaw, J. Cadusseau, R.K. Gherardi, 
Toxicology. 375 (2017) 48–57.  
[18] E. House, M. Esiri, G. Forster, P.G. Ince, C. Exley, Metallomics. 4 
(2012) 56–65.  
[19] A. Mirza, A. King, C. Troakes, C. Exley, J. Alzheimer’s Dis. 54 (2016) 
1333–1338.  
[20] W.W. Daniel, C.L. Cross, Biostatistics: a foundation for analysis in the 
health sciences, John Wiley & Sons Inc., Singapore, 2013. 
[21] D.R.C. McLachlan, C. Bergeron, P.N. Alexandrov, W.J. Walsh, A.I. 
Pogue, M.E. Percy, T.P.A. Kruck, Z. Fang, N.M. Sharfman, V. Jaber, Y. 
Zhao, W. Li, W.J. Lukiw, Mol. Neurobiol. 56 (2019) 1531–1538.  










P a g e  18 | 24 
[23] M. Mold, E. Shardlow, C. Exley, Sci. Rep. 6 (2016) 31578.  
[24] G. Crépeaux, H. Eidi, M.O. David, E. Tzavara, B. Giros, C. Exley, P.A. 
Curmi, C.A. Shaw, R.K. Gherardi, J. Cadusseau, J. Inorg. Biochem. 152 
(2015) 199–205.  
[25] P.I. Oteiza, C.L. Keen, B. Han, M.S. Golub, Metabolism. 42 (1993) 
1296–300.  
[26] K. Demirkaya, B.C. Demirdöğen, Z.Ö. Torun, O. Erdem, E. Çırak, Y.M. 
Tunca, Hum. Exp. Toxicol. 36 (2017) 1071–1080.  
[27] H.B. Röllin, P. Theodorou, T.A. Kilroe-Smith, Br. J. Ind. Med. 48 (1991) 
389–391. 
[28] G. Sahin, I. Varol, A. Temizer, K. Benli, R. Demirdamar, S. Duru, Biol. 
Trace Elem. Res. 41 (1994) 129–135.  
[29] C.S. Martinez, A.G. Escobar, J.A. Uranga-Ocio, F.M. Peçanha, D.V. 
Vassallo, C. Exley, M. Miguel, G.A. Wiggers, Reprod. Toxicol. 73 (2017) 
128–141. 
[30] M. Mold, J. Cottle, C. Exley, Int. J. Environ. Res. Public Health. 16 
(2019) 2129.  
[31] M. Mold, H. Eriksson, P. Siesjö, A. Darabi, E. Shardlow, C. Exley, Sci. 
Rep. 4 (2014). 
[32] I. Mile, A. Svensson, A. Darabi, M. Mold, P. Siesjö, H. Eriksson, J. 
Immunol. Methods. 422 (2015) 87–94.  
[33] M. Mold, A. Chmielecka, M. Rodriguez, F. Thom, C. Linhart, A. King, C. 
Exley, Int. J. Environ. Res. Public Health. 15 (2018) 1777. 










P a g e  19 | 24 
[35] V. Bartanusz, D. Jezova, B. Alajajian, M. Digicaylioglu, Ann. Neurol. 70 
(2011) 194–206.  
[36] W. Pan, W.A. Banks, A.J. Kastin, J. Neuroimmunol. 76 (1997) 105–111. 
[37] P.M. Daniel, D.K.C. Lam, O.E. Pratt, J. Neurol. Sci. 52 (1981) 211–219.  
[38] S. Maya, T. Prakash, K. Das Madhu, D. Goli, Biomed. Pharmacother. 










P a g e  20 | 24 
10. Figure captions 
Figure 1. Aluminum (Al) content in the lumbar spinal cord in sheep of the 
Control group, Adjuvant-only group and Vaccine group. 
Figure 2. Aluminum (Al) content in the parietal lobe in sheep of the 
Control group, Adjuvant-only group and Vaccine group. 
Figure 3. Sheep 111, Adjuvant-only group, gray matter of the lumbar 
spinal cord. (a-b) Lumogallion staining. Two intense yellow-orange 
fluorescent aluminum (Al) deposits (asterisk and arrow head) depicting 
the fluorescence channel (a) and bright field overlay (b). (c-d) Sequential 
unstained sections for autofluorescence evaluation (asterisk and arrow 
head indicates the same area as Al deposits were found with lumogallion). 
A green autofluorescence emission background was identified in non-
stained sections, confirming the specific staining of Al deposits found in 
(a) and (b), respectively. Note weakly autofluorescent intraneuronal 
pigments of lipofuscin (arrow) shown in both the lumogallion stained (a) 
and the non-stained sections (c) under fluorescent channel. Scale bar: 
20µm.  
Figure 4. Sheep 111, Adjuvant-only group, gray matter of the lumbar 
spinal cord. Higher magnification of deposits seen in Figure 3. 
Lumogallion staining. Two intense yellow-orange fluorescent aluminum 
(Al) deposits (asterisk and arrowhead) are seen with the fluorescence 
channel (a-c) and bright field overlay depicted (b-d). One of the deposits 
(asterisk) is cell-associated with a glial-like cell (a-b) whereas the other 
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neuroparenchyma (c-d). A green autofluorescence emission background 
was identified in non-stained sections, confirming the specific staining of 
Al deposits found (shown in Figure 3). Scale bar: 5µm.  
Figure 5. Sheep 114, Adjuvant-only group, gray matter of the parietal 
lobe. (a-b) Lumogallion staining. Cell-associated, intense yellow-orange 
fluorescent Al deposits close to a blood vessel with the fluorescence 
channel (a) and bright field overlay depicted (b). (c-d) Sequential 
unstained sections for autofluorescence evaluation. A green 
autofluorescence emission background was identified in non-stained 
sections, confirming the specific staining of Al deposits found in (a) and 
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11. Synopsis of the Graphical Abstract 
Subcutaneously inoculated aluminum hydroxide containing products 
triggers the formation of a postvaccination granuloma from where 
aluminum translocate to the regional lymph node and selectively 
accumulate in the gray matter of the lumbar spinal cord. Aluminum 
accumulation is higher with adjuvant only than with aluminum containing 
vaccines. 
12. Highlights 
 Aluminum-hydroxide is biodistributed from the subcutis to the central 
nervous system 
 Aluminum is detected quantitatively and qualitatively in the lumbar spinal 
cord 
 Aluminum is mainly found in the gray matter, mostly associated with glial-
like cells 
 Aluminum accumulation is higher after inoculation of adjuvant only than 
whole vaccines 
 Results help to explain the ovine autoimmune/inflammatory syndrome 
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2 0.41 2 2.14 2 0.31 







2 0.08 2 0.37 2 0.91 







2 0.02 2 0.20 2 0.47 







2 0.28 2 0.71 2 1.23 







2 0.21 2 0.79 2 0.19 







2 0.72 2 0.33 2 0.21 







2 0.82 2 0.56 2 0.46 
3 0.06 3 0.48 3 0.32 
 
Table 1. Aluminum (Al) content (µg/g) in the lumbar spinal cord of 
experimental sheep, measured by transversely heated graphite furnace 
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2 0.29 2 0.21 2 0.34 







2 0.23 2 0.01 2 0.33 







2 0.22 2 0.28 2 0.35 







2 0.01 2 0.18 2 0.01 







2 0.12 2 0.13 2 0.10 







2 0.08 2 0.17 2 0.29 







2 0.04 2 0.08 2 0.01 
3 0.01 3 1.36 3 0.10 
 
Table 2. Aluminum (Al) content (μg/g) in the parietal lobe of experimental 
sheep, measured by transversely heated graphite furnace atomic absorption 
spectroscopy (TH-GFAAS). 
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